Rotella Capital Management’s Lipocine LPCN Stock Holding History

Rotella Capital Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-6,114	Closed	-$1.23M	–	508
2015 Q3	$1.23M	Buy	+6,114	New	+$1.41M	0.4%	121

Other funds holding LPCN

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Rotella Capital Management's LPCN Position: Q4 2015 in Review

Rotella Capital Management sold out of Lipocine (LPCN) in Q4 2015, closing a stake of 6,114 shares — an estimated $1.23M sold.

Rotella Capital Management first reported a position in LPCN in Q3 2015 and held it in 1 quarter. The position peaked at $1.23M in Q3 2015. 47 funds tracked by Wall St. Rank hold LPCN as of Q4 2015.

Rotella Capital Management reported no remaining Lipocine position as of Q4 2015 after selling out during the quarter.
Rotella Capital Management sold 6,114 Lipocine shares in Q4 2015, an estimated $1.23M.
Rotella Capital Management first reported a position in Lipocine in Q3 2015 and held it in 1 quarter.
Rotella Capital Management's Lipocine position peaked at $1.23M in Q3 2015.
47 funds tracked by Wall St. Rank held Lipocine as of Q4 2015.

Based on Rotella Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.